Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chronic Obstructive Pulmonary Disease, COPD
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Trial Timeline
May 1, 2007 → Jun 1, 2008
NCT ID
NCT00496470About Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)
Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug) is a approved stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease, COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT00496470. Target conditions include Chronic Obstructive Pulmonary Disease, COPD.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease, COPD were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00496470 | Approved | Completed |
Competing Products
20 competing products in Chronic Obstructive Pulmonary Disease, COPD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |